| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.19B | 1.25B | 1.71B | 1.14B | 1.17B | 1.15B |
| Gross Profit | 91.52M | 117.97M | 238.47M | 266.90M | 137.60M | 71.61M |
| EBITDA | 3.79M | 20.21M | 124.18M | 170.10M | 318.03M | -14.85M |
| Net Income | -29.95M | -13.70M | 74.53M | 148.53M | 303.49M | -36.80M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 5.40B | 5.36B | 2.34B | 2.03B | 1.74B |
| Cash, Cash Equivalents and Short-Term Investments | 77.28M | 272.06M | 99.66M | 62.68M | 64.32M | 186.60M |
| Total Debt | 0.00 | 1.64B | 116.25M | 123.77M | 106.28M | 235.25M |
| Total Liabilities | -3.50B | 1.90B | 1.87B | 276.26M | 252.80M | 385.15M |
| Stockholders Equity | 3.50B | 3.50B | 3.49B | 2.06B | 1.78B | 1.36B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.21B | 1.08B | 140.93M | -228.67M | 145.64M |
| Operating Cash Flow | 0.00 | -1.17B | 1.36B | 244.15M | -188.65M | 146.11M |
| Investing Cash Flow | 0.00 | -26.97M | -2.92B | -95.07M | -39.16M | 29.96M |
| Financing Cash Flow | 0.00 | 1.19B | 1.61B | -143.77M | 105.50M | -44.39M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
60 Neutral | ₹906.84M | 19.05 | ― | ― | 125.93% | 61.50% | |
56 Neutral | ₹1.38B | -13.72 | ― | 0.46% | -52.09% | -142.64% | |
55 Neutral | ₹555.32M | 36.67 | ― | ― | 38.47% | -83.43% | |
45 Neutral | ₹787.60M | -5.17 | ― | ― | -4.97% | 32.59% | |
41 Neutral | ₹423.75M | -15.02 | ― | ― | -14.85% | -128.21% |
GSS Infotech Limited has been asked by the Exchange to provide clarification regarding its compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter ending June 30, 2025. The company is required to address the issue that its Limited Review Report or Independent Auditor’s Report does not conform to the format prescribed by SEBI, and the response from the company is still pending.